NEOT completes pivotal Neotrofin trial

NeoTherapeutics (NEOT) completed enrollment of 521 patients in a pivotal U.S. study of its Neotrofin leteprinim small molecule stimulator of neurotrophic factors. Patients will receive either placebo ...